PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

Tarantelli, C., Gaudio, E., Arribas, A. J., Kwee, I., Hillmann, P., Rinaldi, A., Cascione, L., Spriano, F., Bernasconi, E., Guidetti, F., Carrassa, L., Pittau, R. B., Beaufils, F., Ritschard, R., Rageot, D., Sele, A., Dossena, B., Rossi, F. M., Zucchetto, A., Taborelli, M., Gattei, V., Rossi, D., Stathis, A., Stussi, G., Broggini, M., Wymann, M. P., Wicki, A., Zucca, E., Cmiljanovic, V., Fabbro, D., Bertoni, F.
The American Association for Cancer Research (AACR)
Published 2018